[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"premature-menopause\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:premature-menopause":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100591611","improving-outcomes-in-early-menopause-after-cancer-100591611",false,"NCT06982677","Improving Outcomes in Early Menopause After Cancer","Improving Outcomes for Women Experiencing Premature or Early Menopause After Cancer: Development and Pilot Testing of a Novel Intervention","Inclusion Criteria:\n\n* female (biological sex);\n* 18 to 44 years old;\n* completed cancer treatment (other than endocrine therapy) \\>12 months prior to enrollment;\n* have not had a period for more than 12 months (amenorrhea);\n* able to speak and read English.\n\nExclusion Criteria:\n\n* diagnosis of metastatic cancer;\n* visual or hearing impairment that would interfere with participation in study;\n* cognitive impairment or severe mental illness that would interfere with participation in study.","FEMALE","18 Years","44 Years",{"count":20,"type":21},117,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this study is to create and test a new program led by nurse navigators to help women who experience early menopause after cancer. The program includes personalized menopause education, decision support, and skills to manage menopause symptoms.\n\nThe main questions it aims to answer are:\n\n1. Is the program easy to join, engaging, and well-received by participants?\n2. Does the program group show greater improvements in knowledge, decision-making, confidence, and menopause symptom management compared to the control group?\n\nParticipants will complete sessions of either the program being tested or an educational control program with a nurse navigator via video. Participants will also complete questionnaires when they start the study and again about 10 weeks later.",[27,28,29,30],"Early Menopause","Cancer","Premature Menopause","Surgical Menopause","RECRUITING","2026-05-12",{"date":34,"type":35},"2026-05-14","ACTUAL",{"date":37,"type":35},"2026-01-20",{"date":39,"type":21},"2027-05",{"name":41,"class":42},"Duke University","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":16,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":64,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":43},"100582654","effects-of-estrogen-on-heart-health-in-women-with-primary-ovarian-insufficiency-100582654","NCT06866119","Effects of Estrogen on Heart Health in Women With Primary Ovarian Insufficiency","Effects of Estrogen Replacement on Cardiometabolic Endpoints in Women With Primary Ovarian Insufficiency","ENCODE","Inclusion criteria (I):\n\n* female sex\n* age 30-40\n* CASE PARTICIPANTS ONLY: clinically documented POI diagnosis within 6 months\n* CASE PARTICIPANTS ONLY: planning to clinically initiate 100mcg transdermal 17beta-estradiol twice weekly and micro-ionized progesterone (either 100mg daily or 200mg cyclically)\n* CONTROL PARTICIPANTS ONLY: regular menstrual cycles every 21-35 days\n\nExclusion criteria (E):\n\n* CASE PARTICIPANTS ONLY: genetic POI etiology\n* CASE PARTICIPANTS ONLY: any prior initiation of ERT\n* systemic estrogen, progesterone or testosterone therapy within the past 6 months (including contraception, except for locally acting intrauterine devices - IUDs)\n* lipid lowering therapy within the past 6 months\n* use of antihypertensive medication within the past 6 months\n* current treatment with prescription, systemic (oral, IV, or IM) steroids or anti-inflammatory\u002Fimmune suppressant medical therapies (excluding topical therapies, UV therapy, ASA-derivative therapies, or NSAIDS) for autoimmune\u002Finflammatory diseases (psoriasis, RA, IBD, lupus), post-transplant care, asthma, or pain syndromes\n* use of oral steroids or prescription oral anti-inflammatory\u002Fimmune suppressant medication for \\>7 days within the past 1 month\n* use of IV or IM steroids or IV or IM anti-inflammatory\u002Fimmune suppressant medication within the past 3 months\n* self-reported history of breast and\u002For estrogen dependent malignancy\n* self-reported history of deep vein thromboembolism, pulmonary embolism or stroke\n* self-reported severe liver disease such as cirrhosis\n* self-reported hypercoagulable disorder\n* uncontrolled hypertension at baseline Visit #1- systolic blood pressure (SBP) ≥180 and\u002For diastolic blood pressure (DBP) ≥110\n* tobacco use within 6 months\n* self-reported history of myocardial infarction, stroke, coronary revascularization or diabetes as a CVD risk equivalent\n* stable or unstable angina\n* self-reported history of heart failure\n* pregnancy or breastfeeding\n* concurrent enrollment in conflicting research study",true,"30 Years","40 Years",{"count":56,"type":21},45,"OBSERVATIONAL","The goal of this observational study is to study the effects of treating women with Primary Ovarian Insufficiency (POI) with estrogen replacement therapy to bolster the evidence backing cardiometabolic preventive care in women with POI. The main question it aims to answer is:\n\nDoes 6 months of estrogen replacement therapy for women with POI improved markers of heart health?\n\nWomen newly diagnosed with POI (within 6 months) who are planning to start estrogen replacement therapy from their clinical provider will undergo assessment of markers of heart health before and after 6 months of treatment. These markers will also be compared to those obtained from healthy women without POI.",[60,29,61,62,63],"Primary Ovarian Insufficiency","Metabolic Complications","Endothelial Function (FMD)","Estrogen Replacement Therapy",[65,66,67,68,69,70],"primary ovarian insufficiency","premature menopause","estrogen replacement therapy","cardiovascular disease prevention","POI","ERT","NOT_YET_RECRUITING","2026-01-05",{"date":74,"type":35},"2026-01-07",{"date":76,"type":21},"2026-03-01",{"date":78,"type":21},"2026-06",{"name":80,"class":42},"Massachusetts General Hospital"]